SCHEMBL12426329

SCHEMBL12426329

COc1cc(C(=O)NCCCN2CCC(O)CC2)ccc1N

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR4 Q13639 5/20 0.68
CYP2D6 P10635 1/20 0.61
CYP2C9 P11712 1/20 0.61
CHRM4 P08173 1/20 0.56
CHRM5 P08912 1/20 0.56
ADRA2C P18825 1/20 0.56
CHRM3 P20309 1/20 0.56
HTR1D P28221 1/20 0.56
ADRA1B P35368 1/20 0.56
HTR2B P41595 1/20 0.56
HTR3A P46098 1/20 0.56
SLC29A1 Q99808 1/20 0.55
DRD2 P14416 5/20 0.52
DRD3 P35462 3/20 0.52
MAPT P10636 1/20 0.52
HTR1A P08908 1/20 0.52
ADRA2A P08913 1/20 0.52
SLC6A2 P23975 1/20 0.52
SLC6A4 P31645 1/20 0.52
DRD4 P21917 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12427422 0.89 SLC29A1 (0.66) HTR4CYP2D6CYP2C9SLC29A1DRD2
SCHEMBL12426657 0.88 SLC29A1 (0.65) HTR4CYP2D6CYP2C9SLC29A1DRD2
SCHEMBL12427360 0.88 CYP2D6 (0.64) HTR4CYP2D6CYP2C9ADRA1BHTR2B
SCHEMBL12427425 0.87 CYP2D6 (0.63) HTR4CYP2D6CYP2C9CHRM4CHRM5
SCHEMBL13575609 0.87 CYP2D6 (0.63) HTR4CYP2D6CYP2C9ADRA2CADRA1B
SCHEMBL12426322 0.86 CYP2C9 (0.82) HTR4CYP2D6CYP2C9SLC29A1KMT2A
SCHEMBL13175532 0.82 SMN1; SMN2 (0.65) HTR4CYP2D6CYP2C9SLC29A1DRD2
SCHEMBL3542972 0.82 SMN1; SMN2 (0.68) HTR4CYP2D6CYP2C9SLC29A1DRD2
SCHEMBL12426361 0.81 KMT2A (0.65) HTR4CYP2D6CYP2C9SLC29A1DRD2
SCHEMBL13575582 0.81 SMN1; SMN2 (0.67) HTR4CYP2D6CYP2C9HTR3ASLC29A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003785-B2 Halo-substituted pyrimidodiazepines TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) 2011-08-23 US disclosed
US-20090318408-A1 HALO-SUBSTITUTED PYRIMIDODIAZEPINES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-12-24 US disclosed
WO-2009153197-A1 HALO-SUBSTITUTED PYRIMIDODIAZEPINES AS PLKL INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318408-A1 HALO-SUBSTITUTED PYRIMIDODIAZEPINES PLK1, CCNI, CDK1 HTR4 2822/4885CYP2D6 2081/4885CYP2C9 3029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.